First worldwide Allia Moveo installation at Hôpital Marie-Lannelongue in France highlights progress in redefining interventional care delivery Allia Moveo combines mobility, versatility and AI-powered tools to help clinicians navigate complex minimally invasive procedures with efficiency and accuracy CHICAGO–(BUSINESS WIRE)–GE HealthCare (Nasdaq: GEHC) today announced that Allia™ Moveo has received U.S. […]
Other News
Santé Ventures Raises $330 Million for Fifth Fund to Advance Breakthrough Healthcare Innovation
Firm exceeds $300 million target with Fund V; expands its base of limited partners; announces promotions of Dennis McWilliams and Omar Khalil to Managing Directors AUSTIN, Texas, Feb. 2, 2026 /PRNewswire/ — Santé Ventures, a leading early-stage healthcare and life sciences investment firm, today announced the close of its fifth fund with $330 […]
Brainomix Launches Award-Winning Next Generation Stroke AI Platform with Novel Net Water Uptake Technology at the International Stroke Conference (ISC)
Brainomix 360 Stroke Next Generation has been awarded the prestigious Red Dot Design Award for excellence in usability and innovation An industry-first net water uptake feature unlocks deeper insights into stroke injury that can better inform treatment decisions New research will be…
Imperative Care Launches Zoom 4S Catheter to Further Advance Company’s Zoom Stroke System for Ischemic Stroke Treatment
A Pivotal Step in Optimizing the ADAPT 2.0 Technique for Speed and Simplicity with a Single System Setup ADAPT 2.0 with the Zoom Stroke System CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc. today announced the commercial launch and first patient cases of the new Zoom 4S Catheter – an advanced aspiration thrombectomy […]
HighLife Receives CE Mark Approval for its TMVR Solution
Paris, France, January 26, 2026 – HighLife SAS, a leading MedTech company focused on transcatheter solutions for structural heart disease, today announced that it has received CE Mark approval for the HighLife Transcatheter Mitral Valve Replacement (TMVR) System for the treatment of adult patients suffering from symptomatic moderate-severe or severe mitral valve regurgitation (MR), […]
JenaValve Appoints John Molyneux to Vice President of Operations
IRVINE, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) — JenaValve Technology, Inc., developer and manufacturer of the Trilogy™ Transcatheter Heart Valve (THV) System, today announced the appointment of John Molyneux to Vice President of Operations, overseeing global manufacturing, engineering, and supply chain operations.
The Lancet Publishes TRICORDER Study: Real-World Evaluation Shows Increased Detection When Eko AI-Enabled Stethoscopes Are Used in Primary Care
Large-scale NHS trial led by Imperial College London across 200+ NHS practices shows significant gains in early cardiac disease detection through AI-assisted stethoscope exams SAN FRANCISCO, Jan. 29, 2026 /PRNewswire/ — Eko Health, a leader in AI-powered cardiac and pulmonary disease…
CathVision Demonstrates Clinical Progress in Pulsed Field Ablation With PFAnalyzer – Advancing Lesion Assessment and Restoring Electrogram-Driven Electrophysiology
COPENHAGEN, Denmark, Jan. 29, 2026 /PRNewswire/ — CathVision today announced significant clinical and scientific progress in Pulsed Field Ablation (PFA) with its PFAnalyzer™ software module, reinforcing the company’s differentiated position in electrophysiology (EP) recording and…
Cibolo Health Designates HeartSciences’ MyoVista Insights™ as Endorsed ECG Management Platform for Network of 123 Independent Hospitals
Southlake, TX, Jan. 29, 2026 (GLOBE NEWSWIRE) — HeartSciences Inc. (Nasdaq: HSCS; HSCSW) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company focused on advancing electrocardiography (“ECG” or “EKG”) through the integration of artificial intelligence (“AI”), today announced that Cibolo Rural Health Networks (“Cibolo Health”) has selected MyoVista Insights™ as its endorsed ECG management platform for independent hospitals within its high-value networks.
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation
ACES-EMB is the first randomized-controlled trial to compare dd-cfDNA surveillance to routine biopsy in organ transplantation, highlighting the benefits of Prospera™ in organ rejection AUSTIN, Texas–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the completion of enrollment in ACES-EMB, the first randomized-controlled trial […]



